Xinnuowei announces that its subsidiary, CSPC Jushi Biopharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for SYS6023 from the National Medical Products Administration. Clinical trials will commence soon. SYS6023 is a HER3-targeted antibody-drug conjugate that uses the company’s自主研发的topoisomerase I inhibitor as the payload. It binds to specific receptors on the tumor surface, enters cells via endocytosis, releases the toxin, and kills tumor cells.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
XinNuoWei: The holding subsidiary SYS6023 antibody-drug conjugate received the drug clinical trial approval notice
Xinnuowei announces that its subsidiary, CSPC Jushi Biopharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” for SYS6023 from the National Medical Products Administration. Clinical trials will commence soon. SYS6023 is a HER3-targeted antibody-drug conjugate that uses the company’s自主研发的topoisomerase I inhibitor as the payload. It binds to specific receptors on the tumor surface, enters cells via endocytosis, releases the toxin, and kills tumor cells.